Treatment of walking impairment in multiple sclerosis with dalfampridine
Potassium channel blockade has long been considered a potential therapeutic strategy for treatment of multiple sclerosis (MS) based on the pathophysiology of demyelinated axons. Dalfampridine, which is also known as fampridine or 4-aminopyridine (4-AP), is the potassium channel blocker that has been...
שמור ב:
| מחבר ראשי: | |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publishing
2011-03-01
|
| סדרה: | Therapeutic Advances in Neurological Disorders |
| גישה מקוונת: | https://doi.org/10.1177/1756285611403960 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|